Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review.
Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC. · 2020
Read Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review. by Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7276742.txt.
Introduction
Juan and co-authors review what was known early on about COVID-19 in pregnancy. Their systematic review appeared in Ultrasound in Obstetrics and Gynecology. They searched medical databases up to April 20, 2020 for reports with confirmed infection and at least one outcome for mother or baby.
Only 24 studies, covering 324 pregnant women, met their criteria. Most of the literature was single case reports and small series. The review gathers maternal illness patterns, delivery outcomes, and newborn results from that early evidence. It also asks whether the virus can pass from mother to baby before birth. Given the thin base, the authors treat their summary as a starting point that larger studies would need to confirm.
Catalog record
| CREATOR | Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Effect of coronavirus disease 2019 (COVID‐19) on maternal, perinatal and neonatal outcome: systematic review By J. Juan, M. M. Gil, Z. Rong, Y. Zhang, H. Yang, L. C. Poon Published in: Ultrasound in Obstetrics & Gynecology DOI: 10.1002/uog.22088 ABSTRACT ABSTRACT Objective To evaluate the effect of coronavirus disease 2019 (COVID‐19) on maternal, perinatal and neonatal outcome by performing a systematic review of available published literature on pregnancies affected by COVID‐19. Methods We performed a systematic review to evaluate the effect of COVID‐19 on pregnancy, perinatal and neonatal outcome. We conducted a comprehensive literature search using PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure Database and Wan Fang Data up to and including 20 April 2020 (studies were identified through PubMed alert after that date). For the search strategy, combinations of the following keywords and medical subject heading (MeSH) terms were used: ‘SARS‐CoV‐2’, ‘COVID‐19’, ‘coronavirus disease 2019’, ‘pregnancy’, ‘gestation’, ‘maternal’, ‘mother’, ‘vertical transmission’, ‘maternal–fetal transmission’, ‘intrauterine transmission’, ‘neonate’, ‘infant’ and ‘delivery’. Eligibility criteria included laboratory‐confirmed and/or clinically diagnosed COVID‐19, patient being pregnant on admission and availability of clinical characteristics, including at least one maternal, perinatal or neonatal outcome. Exclusion criteria were non‐peer‐reviewed or unpublished reports, unspecified date and location of the study, suspicion of duplicate reporting and unreported maternal or perinatal outcomes. No language restrictions were applied. Results We identified a high number of relevant case reports and case series, but only 24 studies, including a total of 324 pregnant women with COVID‐19, met the eligibility criteria and were included in the systematic review. These comprised nine case series (eight consecutive) and 15 case reports. A total of 20 pregnant patients with laboratory‐confirmed COVID‐19 were included in the case reports. In the combined data from the eight consecutive case series, including 211 (71.5%) cases of laboratory‐confirmed and 84 (28.5%) of clinically diagnosed COVID‐19, the maternal age ranged from 20 to 44 years and the gestational age on admission ranged from 5 to 41 weeks. The most common symptoms at presentation were fever, cough, dyspnea/shortness of breath, fatigue and myalgia. The rate of severe pneumonia reported amongst the case series ranged from 0% to 14%, with the majority of the cases requiring admission to the intensive care unit. Almost all cases from the case series had positive computed tomography chest findings. All six and 22 cases that had nucleic‐acid testing in vaginal mucus and breast milk samples, respectively, were negative for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Only four cases of spontaneous miscarriage or termination were reported. In the consecutive case series, 219/295 women had delivered at the time of reporting and 78% of them had Cesarean section. The gestational age at delivery ranged from 28 to 41 weeks. Apgar scores at both 1 and 5 min ranged from 7 to 10. Only eight neonates had birth weight < 2500 g and nearly one‐third of neonates were transferred to the neonatal intensive care unit. There was one case of neonatal asphyxia and death. In 155 neonates that had nucleic‐acid testing in throat swab, all, except three cases, were negative for SARS‐CoV‐2. There were no cases of maternal death in the eight consecutive case series. Seven maternal deaths, four intrauterine fetal deaths (one with twin pregnancy) and two neonatal deaths (twin pregnancy) were reported in a non‐consecutive case series of nine cases with severe COVID‐19. In the case reports, two maternal deaths, one neonatal death and two cases of neonatal SARS‐CoV‐2 infection were reported. Conclusions Despite the increasing number of published studies on COVID‐19 in pregnancy, there are insufficient good‐quality data to draw unbiased conclusions with regard to the severity of the disease or specific complications of COVID‐19 in pregnant women, as well as vertical transmission, perinatal and neonatal complications. In order to answer specific questions in relation to the impact of COVID‐19 on pregnant women and their fetuses, through meaningful good‐quality research, we urge researchers and investigators to present complete outcome data and reference previously published cases in their publications, and to record such reporting when the data of a case are entered into one or several registries. © 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of the International Society of Ultrasound in Obstetrics and Gynecology. CONTRIBUTION What are the novel findings of this work? Based on consecutive case series, the rate of severe pneumonia in pregnant women with coronavirus disease 2019 (COVID‐19) was 0–14%; the majority of pregnancies were delivered by Cesarean section, there was one case of neonatal asphyxia and death, 155 neonates had nucleic‐acid testing in throat swabs and all, except three cases, were negative for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). There were seven maternal deaths, four intrauterine fetal deaths and two neonatal deaths reported in a non‐consecutive case series of nine cases with severe COVID‐19. Amongst the case reports, two maternal deaths, one neonatal death and two cases of neonatal SARS‐CoV‐2 infection were reported. What are the clinical implications of this work? Despite the increasing number of published studies on COVID‐19 in pregnancy, there are insufficient good‐quality data to draw unbiased conclusions with regard to complications of COVID‐19 in pregnant women, as well as vertical transmission and perinatal complications. There is a need for good‐quality research. We urge researchers and investigators to present complete outcome data and reference previously published cases in their publications, and to record such reporting when the data of a case are entered into one or several registries. INTRODUCTION With over 3 million individuals infected worldwide as of 2 May 2020 1 , the coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is a global public health crisis 2 , 3 . Most cohort studies have focused on evaluating the effects of COVID‐19 on the general population 2 , 3 , 4 and there are insufficient data on its impact on vulnerable populations, such as pregnant women. It is recognized that pregnant women are at an increased risk of acquiring viral respiratory infection and developing severe pneumonia, due to the physiologic changes in their immune and cardiopulmonary systems 5 , 6 . Lessons learned from the two previous notable coronavirus outbreaks, the severe acute respiratory syndrome coronavirus (SARS‐CoV) and the Middle East respiratory syndrome coronavirus (MERS‐CoV), suggest that pregnant women are particularly susceptible to adverse outcome, including the need for endotracheal intubation, admission to an intensive care unit (ICU), renal failure and death 7 , 8 , 9 . The first study describing the clinical characteristics and investigating the possibility of vertical transmission of SARS‐CoV‐2 in nine pregnant women, with laboratory‐confirmed COVID‐19, demonstrated that the severity of COVID‐19 in pregnant women was similar to that in non‐pregnant adults; and that there was no evidence of vertical transmission, as SARS‐CoV‐2 was not detected in amniotic‐fluid, cord‐blood and neonatal throat‐swab samples in six cases 10 . To date, the largest series reporting on both pregnancy and neonatal outcomes, including a total of 99 SARS‐CoV‐2‐infected pregnant women, demonstrated that COVID‐19 during pregnancy was not associated with an increased risk of adverse outcomes, such as spontaneous preterm birth 11 . None of the 100 neonates born to these women was infected with SARS‐CoV‐2. Based on very scarce data